DGAP-Adhoc

SYGNIS AG: SYGNIS AG receives binding commitment for the purchase of shares for up to EUR 3.5 million within the scope of the ongoing capital increases to finance the acquisition of Innova Biosciences Ltd.

DGAP-Ad-hoc: SYGNIS AG / Key word(s): Agreement SYGNIS AG: SYGNIS AG receives binding commitment for the purchase of shares for up to EUR 3.5 million within the scope of the ongoing capital increases to finance the acquisition of Innova Biosciences Ltd. 24-May-2017 / 19:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.   Ad hoc announcement according to § 17 MAR

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE USA, CANADA, JAPAN AND AUSTRALIA

SYGNIS AG receives binding commitment for the purchase of shares for up to EUR 3.5 million within the scope of the ongoing capital increases to finance the acquisition of Innova Biosciences Ltd.

Madrid, Spain, and Heidelberg, Germany, 24 May, 2017 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today received a binding commitment for the purchase of shares up to a total of EUR 3.5 million as part of the previously announced cash capital increases to finance the acquisition of Innova Biosciences Ltd. Under the terms of the agreement signed today, the investor has committed to purchase up to 2,536,000 new shares at a price of EUR 1.38 per new share. The obligation is subject to the condition that the DAX closing price on the settlement day is not more than 10% lower than the DAX closing price as of today.

**** End of ad hoc announcement ****

For further information on this transaction please also visit http://capital.sygnis.com.

For further information, please contact:

SYGNIS AG

Dr. Heikki Lanckriet

Co-CEO/CSO

Phone : [phone]

Email: [e-mail]

Pilar de la Huerta

Co-CEO/CBDO

Phone: [phone]

Email: [e-mail]

MC Services AG

Raimund Gabriel

Managing Partner

Phone: [phone]